We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aclaris Therapeutics (ACRS - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aclaris Therapeutics is one of 916 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aclaris Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACRS' full-year earnings has moved 3.8% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACRS has returned about 25.3% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.4%. This shows that Aclaris Therapeutics is outperforming its peers so far this year.
Another stock in the Medical sector, Glaukos (GKOS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 53.6%.
The consensus estimate for Glaukos' current year EPS has increased 44.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aclaris Therapeutics belongs to the Medical - Drugs industry, which includes 133 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, this group has lost an average of 2.5% so far this year, meaning that ACRS is performing better in terms of year-to-date returns.
Glaukos, however, belongs to the Medical - Instruments industry. Currently, this 78-stock industry is ranked #99. The industry has moved -2.1% so far this year.
Investors with an interest in Medical stocks should continue to track Aclaris Therapeutics and Glaukos. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Aclaris Therapeutics (ACRS - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aclaris Therapeutics is one of 916 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aclaris Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACRS' full-year earnings has moved 3.8% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACRS has returned about 25.3% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.4%. This shows that Aclaris Therapeutics is outperforming its peers so far this year.
Another stock in the Medical sector, Glaukos (GKOS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 53.6%.
The consensus estimate for Glaukos' current year EPS has increased 44.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aclaris Therapeutics belongs to the Medical - Drugs industry, which includes 133 individual stocks and currently sits at #96 in the Zacks Industry Rank. On average, this group has lost an average of 2.5% so far this year, meaning that ACRS is performing better in terms of year-to-date returns.
Glaukos, however, belongs to the Medical - Instruments industry. Currently, this 78-stock industry is ranked #99. The industry has moved -2.1% so far this year.
Investors with an interest in Medical stocks should continue to track Aclaris Therapeutics and Glaukos. These stocks will be looking to continue their solid performance.